# OnCo record nct03016819 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03016819/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03016819", "NCT03016819" ;
  schema:name "Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)"@en ;
  schema:alternateName "APROMISS"@en ;
  schema:description "A phase 3 trial of Anlotinib, Dacarbazine in sarcomas, run by Advenchen Laboratories, LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03016819/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03016819> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2017-08-15" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/alveolar-soft-part-sarcoma/>, <https://onco.cc/cancers/leiomyosarcoma/>, <https://onco.cc/cancers/synovial-sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/anlotinib/>, <https://onco.cc/drugs/dacarbazine/> ;
  onco:companies <https://onco.cc/companies/advenchen-laboratories/> .